Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.15
NAS:DEPO's Cash-to-Debt is ranked lower than
88% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:DEPO: 0.15 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:DEPO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 10.39 Max: No Debt
Current: 0.15
Equity-to-Asset 0.21
NAS:DEPO's Equity-to-Asset is ranked lower than
91% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. NAS:DEPO: 0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:DEPO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.52  Med: 0.36 Max: 0.89
Current: 0.21
-0.52
0.89
Interest Coverage 0.29
NAS:DEPO's Interest Coverage is ranked lower than
99% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.29 vs. NAS:DEPO: 0.29 )
Ranked among companies with meaningful Interest Coverage only.
NAS:DEPO' s Interest Coverage Range Over the Past 10 Years
Min: 0.29  Med: 8.12 Max: No Debt
Current: 0.29
Piotroski F-Score: 5
Altman Z-Score: 0.97
Beneish M-Score: -2.67
WACC vs ROIC
10.96%
33.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 5.38
NAS:DEPO's Operating Margin % is ranked lower than
58% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. NAS:DEPO: 5.38 )
Ranked among companies with meaningful Operating Margin % only.
NAS:DEPO' s Operating Margin % Range Over the Past 10 Years
Min: -49.06  Med: 4.94 Max: 72.49
Current: 5.38
-49.06
72.49
Net Margin % -19.46
NAS:DEPO's Net Margin % is ranked lower than
81% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:DEPO: -19.46 )
Ranked among companies with meaningful Net Margin % only.
NAS:DEPO' s Net Margin % Range Over the Past 10 Years
Min: -43.92  Med: -7.32 Max: 75.05
Current: -19.46
-43.92
75.05
ROE % -30.52
NAS:DEPO's ROE % is ranked lower than
82% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. NAS:DEPO: -30.52 )
Ranked among companies with meaningful ROE % only.
NAS:DEPO' s ROE % Range Over the Past 10 Years
Min: -90.05  Med: -1.11 Max: 532.43
Current: -30.52
-90.05
532.43
ROA % -6.92
NAS:DEPO's ROA % is ranked lower than
77% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. NAS:DEPO: -6.92 )
Ranked among companies with meaningful ROA % only.
NAS:DEPO' s ROA % Range Over the Past 10 Years
Min: -23.58  Med: -1.26 Max: 73.87
Current: -6.92
-23.58
73.87
ROC (Joel Greenblatt) % 21.58
NAS:DEPO's ROC (Joel Greenblatt) % is ranked higher than
63% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. NAS:DEPO: 21.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:DEPO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2282.52  Med: 65.03 Max: 8060.52
Current: 21.58
-2282.52
8060.52
3-Year Revenue Growth Rate 47.20
NAS:DEPO's 3-Year Revenue Growth Rate is ranked higher than
95% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. NAS:DEPO: 47.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:DEPO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -74.4  Med: 43.7 Max: 517.8
Current: 47.2
-74.4
517.8
3-Year EBITDA Growth Rate 95.70
NAS:DEPO's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. NAS:DEPO: 95.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:DEPO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.3  Med: 6.7 Max: 95.7
Current: 95.7
-55.3
95.7
GuruFocus has detected 2 Warning Signs with Depomed Inc $NAS:DEPO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:DEPO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DEPO Guru Trades in Q1 2016

Steven Cohen 1,866,629 sh (New)
John Hussman 200,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2016

DEPO Guru Trades in Q2 2016

Joel Greenblatt 47,318 sh (New)
Steven Cohen Sold Out
John Hussman Sold Out
» More
Q3 2016

DEPO Guru Trades in Q3 2016

John Hussman 100,000 sh (New)
Jeremy Grantham 102,300 sh (New)
Joel Greenblatt 77,542 sh (+63.87%)
Jeremy Grantham 500,000 sh (unchged)
» More
Q4 2016

DEPO Guru Trades in Q4 2016

Mario Gabelli 15,000 sh (New)
Jeremy Grantham 256,509 sh (+150.74%)
John Hussman 150,000 sh (+50.00%)
Jeremy Grantham 500,000 sh (unchged)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:MNTA, OTCPK:TWMJF, NYSE:DPLO, OTCPK:NPPNY, NAS:SGYP, OTCPK:GNMLF, OTCPK:KHTRF, OTCPK:EVTCY, NYSE:LCI, NAS:HRTX, NAS:EGRX, NAS:IPXL, NAS:FLXN, NAS:AMPH, OTCPK:KSPHF, OTCPK:APHQF, NAS:SUPN, OTCPK:ACBFF, NAS:LBIO, NAS:INNL » details
Traded in other countries:DPO.Germany,
DepoMed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Depomed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.

Ratios

vs
industry
vs
history
Forward PE Ratio 14.60
DEPO's Forward PE Ratio is ranked lower than
51% of the 89 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. DEPO: 14.60 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 42.78
DEPO's Price-to-Owner-Earnings is ranked lower than
65% of the 296 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.92 vs. DEPO: 42.78 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DEPO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.68  Med: 7.76 Max: 212
Current: 42.78
2.68
212
PB Ratio 3.71
DEPO's PB Ratio is ranked lower than
63% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. DEPO: 3.71 )
Ranked among companies with meaningful PB Ratio only.
DEPO' s PB Ratio Range Over the Past 10 Years
Min: 2  Med: 4.29 Max: 22.64
Current: 3.71
2
22.64
PS Ratio 2.01
DEPO's PS Ratio is ranked higher than
61% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. DEPO: 2.01 )
Ranked among companies with meaningful PS Ratio only.
DEPO' s PS Ratio Range Over the Past 10 Years
Min: 1.38  Med: 3.28 Max: 47.55
Current: 2.01
1.38
47.55
Price-to-Free-Cash-Flow 14.59
DEPO's Price-to-Free-Cash-Flow is ranked higher than
69% of the 228 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.42 vs. DEPO: 14.59 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DEPO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.31  Med: 10.85 Max: 265.87
Current: 14.59
2.31
265.87
Price-to-Operating-Cash-Flow 13.94
DEPO's Price-to-Operating-Cash-Flow is ranked higher than
60% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.18 vs. DEPO: 13.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DEPO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.28  Med: 10.57 Max: 251.36
Current: 13.94
2.28
251.36
EV-to-EBIT 100.58
DEPO's EV-to-EBIT is ranked lower than
94% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. DEPO: 100.58 )
Ranked among companies with meaningful EV-to-EBIT only.
DEPO' s EV-to-EBIT Range Over the Past 10 Years
Min: -302.2  Med: -2.8 Max: 116.9
Current: 100.58
-302.2
116.9
EV-to-EBITDA 15.03
DEPO's EV-to-EBITDA is ranked higher than
53% of the 573 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.30 vs. DEPO: 15.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: 2.05 Max: 124.5
Current: 15.03
-582.9
124.5
Shiller PE Ratio 112.73
DEPO's Shiller PE Ratio is ranked lower than
87% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.64 vs. DEPO: 112.73 )
Ranked among companies with meaningful Shiller PE Ratio only.
DEPO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 75.75  Med: 121.07 Max: 1535
Current: 112.73
75.75
1535
Current Ratio 1.35
DEPO's Current Ratio is ranked lower than
77% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. DEPO: 1.35 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.68 Max: 12.5
Current: 1.35
1.35
12.5
Quick Ratio 1.29
DEPO's Quick Ratio is ranked lower than
65% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. DEPO: 1.29 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 1.29  Med: 2.54 Max: 12.5
Current: 1.29
1.29
12.5
Days Inventory 46.83
DEPO's Days Inventory is ranked higher than
86% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. DEPO: 46.83 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 46.83  Med: 208.69 Max: 544.34
Current: 46.83
46.83
544.34
Days Sales Outstanding 81.71
DEPO's Days Sales Outstanding is ranked lower than
53% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. DEPO: 81.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 81.71
Current: 81.71
12.13
81.71
Days Payable 62.03
DEPO's Days Payable is ranked lower than
60% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. DEPO: 62.03 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 91.87 Max: 159.38
Current: 62.03
30.8
159.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.40
DEPO's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. DEPO: -2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DEPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.9  Med: -7.5 Max: -2.2
Current: -2.4
-58.9
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.44
DEPO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
70% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. DEPO: 1.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DEPO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.42  Med: 2.8 Max: 335
Current: 1.44
1.42
335
Price-to-Median-PS-Value 0.61
DEPO's Price-to-Median-PS-Value is ranked higher than
87% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. DEPO: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DEPO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.6  Med: 2.99 Max: 270
Current: 0.61
0.6
270
Earnings Yield (Greenblatt) % 1.00
DEPO's Earnings Yield (Greenblatt) % is ranked lower than
61% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. DEPO: 1.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DEPO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.9  Med: 15.75 Max: 266.4
Current: 1
0.9
266.4

More Statistics

Revenue (TTM) (Mil) $455.9
EPS (TTM) $ -1.44
Beta1.47
Short Percentage of Float23.64%
52-Week Range $12.25 - 27.02
Shares Outstanding (Mil)62.10

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 513 580 599
EPS ($) 1.06 1.39 1.55
EPS without NRI ($) 1.06 1.39 1.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
CFO Says Depomed to Buy or Be Sold Mar 23 2017
Depomed to Present at Healthcare Conferences in March Mar 06 2017
DEPOMED INC Financials Mar 02 2017
On Generic Drugs, Patent 'Death Squads' And The Oscars Feb 27 2017
DEPOMED INC Files SEC form 10-K, Annual Report Feb 24 2017
Depomed, Inc. :DEPO-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017 Feb 23 2017
Depomed, Inc. :DEPO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017 Feb 23 2017
Could 2017 Prove to be a Bull Market for Biotechs? Today's Reports on Depomed and Amicus... Feb 23 2017
Argos Plummets 72%, Leads Biotech Movers Feb 22 2017
Edited Transcript of DEPO earnings conference call or presentation 21-Feb-17 9:30pm GMT Feb 22 2017
Depomed Reports 33% Increase in 2016 Net Product Sales Feb 21 2017
Depomed Inc Earnings Call scheduled for 4:30 pm ET today Feb 21 2017
Depomed reports 4Q loss Feb 21 2017
Depomed reports 4Q loss Feb 21 2017
DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 21 2017
Depomed Reports Fourth Quarter and Full Year 2016 Financial Results Feb 21 2017
Q4 2016 Depomed Inc Earnings Release - After Market Close Feb 21 2017
Depomed to Report Fourth Quarter Fiscal Year 2016 Financial Results on Tuesday, February 21, 2017 Feb 17 2017
DepoMed downgraded by Mizuho Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)